LLY News and Press, Eli Lilly and Company From 04/03/24

2024-04-03 07:01:03 ET More on Novo Nordisk Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Novo Nordisk, A Very Healthy Pharma Stalwart CVS, Elevance Health to c...

2024-04-02 07:34:50 ET More on Verve Therapeutics Verve's Proof-Of-Concept Data Doesn't Inspire Confidence Vectoring In On Verve Therapeutics Seeking Alpha’s Quant Rating on Verve Therapeutics Historical earnings data for Verve Therapeutics Fin...

2024-04-02 06:01:11 ET Summary Viking Therapeutics' share price has rapidly increased from recent weight loss drug excitement. The company’s value seems to be derived from its weight loss and NASH/MASH candidates. VK2735, the weight loss candidate, presents a potentiall...

2024-04-01 10:44:01 ET More on S&P 500 Index: China PMI Is Better Than Expected But The Greenback Still Rises Above CNY7.23 The March Labor Report Preview: The Cracks Are Deepening S&P 500 Closes Its Best Quarter Since 2019 At Record High The most sho...

2024-04-01 10:30:03 ET Wells Fargo analyst issues BUY recommendation for LLY on April 1, 2024 09:00AM ET. The previous analyst recommendation was Buy. LLY was trading at $763.7199 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...

2024-04-01 06:08:19 ET Summary Cytokinetics' stock has seen much buyout speculation in recent months, with companies like Eli Lilly, Novartis, Johnson & Johnson, Amgen, and AstraZeneca being potential suitors. The company's Phase 3 study for aficamten, a treatment for heart di...

2024-04-01 04:30:00 ET The original "Magnificent Seven" is a group of tech stocks that have generally delivered market-beating returns in the past decade. Creating a similarly prominent group in another sector like healthcare isn't an exact science. So, some might not agree with the list be...

2024-03-31 11:15:13 ET Summary Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity candidate MariTide and other promising treatments in it...

2024-03-31 10:47:12 ET Summary Eli Lilly's stock has surged in the first quarter of 2024 due to the success of its weight loss products in the pharma market. A huge rally has powered the shares to a gain of 130% over the past 12 months and the stock to a $700 billion market cap. ...

2024-03-31 09:45:00 ET Bear markets come and go, but history has taught investors time and time again that bull markets not only tend to outlast these periods, but eventually drive stocks higher than before the downturn hit. Both bull and bear markets can present opportunities for the long-...